Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04457258 · ClinicalTrials.gov registry record · Early Phase 1
68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma
A Early Phase 1 study of Sarcoma and Metastatic Sarcoma, sponsored by Jonsson Comprehensive Cancer Center.
- Active
- Registry status
- Early Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT04457258: Active Early Phase 1 study of Sarcoma and Metastatic Sarcoma, sponsored by Jonsson Comprehensive Cancer Center.
NCT04457258 is a Early Phase 1 study of Sarcoma and Metastatic Sarcoma that is active but no longer recruiting, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 18 participants, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04457258, a Early Phase 1 study of Sarcoma and Metastatic Sarcoma, is active but no longer recruiting, sponsored by Jonsson Comprehensive Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
This early phase I trial studies an imaging technique called 68Ga-FAPi-46 PET/CT to determine where and to which degree the FAPI tracer (68Ga-FAPi-46) accumulates in normal and cancer tissues in patients with sarcoma. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research, 68Ga-FAPi. Because some cancers take up 68Ga-FAPi it can be seen with PET. CT utilizes x-rays that traverse body from the outside. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in patient's body.
Primary Outcome
Will be quantified by mean and maximum standardized uptake values (SUVmean and SUVmax).
Conditions Studied
Interventions
- PROCEDURE Computed Tomography
- PROCEDURE Positron Emission Tomography
- DRUG Gallium Ga 68 FAPi-46
- RADIATION 18F-FDG
Study Locations (1)
California
- UCLA / Jonsson Comprehensive Cancer Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2020-09-08 |
| Est. Completion | 2027-07-21 |
| Phase | Early Phase 1 |
What the registry record for NCT04457258 still lists
NCT04457258 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (98% lower).
The record links to 3 conditions, with Sarcoma appearing as the primary indexed condition, and to 4 interventions - of which Computed Tomography is the first listed.
NCT04457258 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04457258 about?
NCT04457258 is a clinical study titled "68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma". This early phase I trial studies an imaging technique called 68Ga-FAPi-46 PET/CT to determine where and to which degree the FAPI tracer (68Ga-FAPi-46) accumulates in normal and cancer tissues in patients with sarcoma. PET is an established imaging technique that utilizes small amounts of radioactivi...
What is the current status of trial NCT04457258?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 18 participants. The study started on 2020-09-08. Estimated completion is 2027-07-21.
What conditions does trial NCT04457258 study?
This clinical trial studies the following conditions: Sarcoma, Metastatic Sarcoma, Recurrent Sarcoma.
What interventions are being tested in trial NCT04457258?
The interventions under investigation include: Computed Tomography (PROCEDURE), Positron Emission Tomography (PROCEDURE), Gallium Ga 68 FAPi-46 (DRUG), 18F-FDG (RADIATION).
Who is sponsoring clinical trial NCT04457258?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04457258 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04457258's enrollment target sits among peer trials
18 105th of 122 higher than 18 of 122 other Sarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma
ACTIVE NOT RECRUITING · Early Phase 1
-
Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor
ACTIVE NOT RECRUITING · Early Phase 1
-
Gemcitabine Plus Ascorbate for Sarcoma in Adults (Pilot)
ACTIVE NOT RECRUITING · Early Phase 1
-
WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)
RECRUITING · NA
-
LCI-SAR-BSTS-CTDNA-001: Circulating Tumor DNA Liquid Biopsy in Sarcoma Patients
RECRUITING
-
Palbociclib and Pembrolizumab in Sarcoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy